» Articles » PMID: 18991254

Optimal Implantation Site for Pancreatic Islet Transplantation

Overview
Journal Br J Surg
Specialty General Surgery
Date 2008 Nov 11
PMID 18991254
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Since the first report of successful pancreatic islet transplantation to reverse hyperglycaemia in diabetic rodents, there has been great interest in determining the optimal site for implantation. Although the portal vein remains the most frequently used site clinically, it is not ideal. About half of the islets introduced into the liver die during or shortly after transplantation. Although many patients achieve insulin independence after portal vein infusion of islets, in the long term most resume insulin injections.

Methods: This review considers possible sites and techniques of islet transplantation in small and large animal models, and in humans. Metabolic, immunological and technical aspects are discussed.

Results And Conclusion: Many groups have sought an alternative site that might offer improved engraftment and long-term survival, together with reduced procedure-related complications. The spleen, pancreas, kidney capsule, peritoneum and omental pouch have been explored. The advantages and disadvantages of various sites are discussed in order to define the most suitable for clinical use and to direct future research.

Citing Articles

Standard Protocols for Characterising Primary and In Vitro-Generated Human Hepatocytes.

Heydari Z, Gramignoli R, Piryaei A, Zahmatkesh E, Pooyan P, Seydi H J Cell Mol Med. 2025; 29(3):e70390.

PMID: 39910642 PMC: 11798750. DOI: 10.1111/jcmm.70390.


High-Yield Generation of Glucose-Responsive Pseudoislets From Murine Insulinoma Cells for Studies and Longitudinal Monitoring of Graft Survival .

Gonzalez G, Li C, Pasolini I, Pete S, Verheyen C, Vignolo S Cell Transplant. 2025; 34:9636897251315123.

PMID: 39881520 PMC: 11780636. DOI: 10.1177/09636897251315123.


Cutting edge of immune response and immunosuppressants in allogeneic and xenogeneic islet transplantation.

Yue L, Li J, Yao M, Song S, Zhang X, Wang Y Front Immunol. 2024; 15:1455691.

PMID: 39346923 PMC: 11427288. DOI: 10.3389/fimmu.2024.1455691.


Hypoxia within subcutaneously implanted macroencapsulation devices limits the viability and functionality of densely loaded islets.

Einstein S, Steyn L, Weegman B, Suszynski T, Sambanis A, OBrien T Front Transplant. 2024; 2:1257029.

PMID: 38993891 PMC: 11235299. DOI: 10.3389/frtra.2023.1257029.


Targeted mapping and utilization of the perihepatic surface for therapeutic beta cell replacement and retrieval in diabetic non-human primates.

Leishman D, Oppler S, Stone L, OBrien T, Ramachandran S, Willenberg B Front Transplant. 2024; 3():1352777.

PMID: 38993753 PMC: 11235263. DOI: 10.3389/frtra.2024.1352777.